Cardio Round-Up: FDA Approves Two New Indications for XARELTO® in Pediatric VTE Patients; and More

FDA Approves Two New Indications for XARELTO® (rivaroxaban) to Help Prevent and Treat VTE in Pediatric Patients

The Janssen Pharmaceutical Companies of Johnson & Johnson recently announced that the U.S. Food and Drug Administration (FDA) has proved two pediatric indications for XARELTO® (rivaroxaban) for the treatment of venous thromboembolism (VTE)in patients from birth to less than 18 years after at least five days of parenteral anticoagulant treatment.

Frail Patients With Nonvalvular A-Fib Less Likely to Receive Anticoagulants

Frail patients with a new diagnosis of nonvalvular atrial fibrillation (NVAF) are less likely to receive an anticoagulant, according to a study published online Dec. 20 in the Canadian Journal of Cardiology.

“As frail patients have higher event rates and thus stand to potentially derive greater benefit from anticoagulation than their nonfrail counterparts, we encourage clinicians to evaluate absolute risks and benefits when making prescribing decisions,” a coauthor said in a statement.

Comparing Hot Balloon and Cryoballoon Ablation for Atrial Fibrillation

According to a study in Frontiers in Cardiovascular Medicine, alternative balloon-based approaches are effective ablations for atrial fibrillation (AFib), and offer advantages over conventional catheter ablation techniques. Lead author, Dr. Xinyi Peng, and colleagues asserted that different characteristics between these types of ablation, such as hot balloon ablation (HBA) and cyroballoon ablation (CBA), are not well understood. Thus, Dr. Peng and his team conducted a meta-analysis and came to the opinion that both HBA and CBA were effective ablations for AFib, and that they yielded comparable outcomes.